Empagliflozin/Metformin Duo Tablets 5/850 mg
Empagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
MFDS item code 202201396 · Approved 2022.04.04
Improvement of glycemic control in adults with type 2 diabetes
This medication is used as an adjunct to diet and exercise to assist in blood sugar control for patients with type 2 diabetes. It is particularly suitable for adult patients who do not achieve sufficient blood sugar control and can also be administered to patients with accompanying cardiovascular disease. However, it is important to refer to specialist recommendations concerning the risk of cardiovascular events. This medication helps improve blood sugar control, aiding in diabetes treatment.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their current doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse effects associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication helps control blood sugar levels. It may cause a rare side effect known as lactic acidosis, which is a serious condition where lactic acid builds up excessively in the body. Lactic acidosis is severe and can sometimes be fatal, so immediate consultation with a physician is necessary if symptoms occur. Additionally, the risk of hypoglycemia may increase when this medication is taken with other diabetes medications such as insulin or sulfonylureas. Symptoms of hypoglycemia include dizziness, cold sweat, and severe fatigue. This medication should not be used in patients with significantly impaired kidney function or in acute conditions such as infections, dehydration, heart failure, or acute myocardial infarction. Women who are pregnant or may become pregnant and nursing mothers should also avoid this medication. During treatment, regular monitoring of kidney function is necessary, as treatment may be stopped if there is a decline in kidney function. When undergoing imaging tests with iodine contrast agents, this medication should be suspended for a certain period before and after the test, and it should be resumed only after confirming normal kidney function. This medication may lead to fluid loss, so patients at risk for dehydration or low blood pressure should use caution. Elderly patients or those with cardiovascular conditions should be especially careful. During treatment, urinary and genital infections may occur, and any related symptoms should be reported to a physician immediately. The metformin component may cause gastrointestinal disturbances (diarrhea, nausea, vomiting, etc.) and may lower vitamin B12 levels, so regular monitoring may be required. Alcohol use can increase the risk of lactic acidosis; therefore, it is advisable to avoid drinking alcohol while on this medication. Women who are pregnant or nursing should not take this medication, and if they are currently taking it, they should consult their doctor. This medication is not recommended for children under 18 years of age. In the case of overdose, there is a risk of lactic acidosis or hypoglycemia, and immediate medical attention is required, possibly needing treatment via hemodialysis. Patients should have their blood sugar and kidney function, as well as vitamin B12 levels, regularly monitored during treatment, and should consult their doctor immediately if any abnormal symptoms occur. Additionally, this medication may interact with other drugs, so it is essential to inform healthcare providers of other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or humidity, so it must be stored in a tightly sealed container. It is important to maintain storage temperatures between 1 to 30 degrees Celsius at room temperature to preserve the medication's effectiveness for a longer period.
White, oval, biconvex, film-coated tablets with a yellow tint
10 tablets/box[(10 tablets/PTP x 1)], 60 tablets/box[(10 tablets/PTP x 6)], 60 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.